Related Experiment Video

Updated: Jul 8, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization

Jeffrey B Stavenhagen1, Sergey Gorlatov, Nadine Tuaillon

  • 1MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850, USA. stavenhagenj@macrogenics.com

Advances in Enzyme Regulation
|January 8, 2008
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Generation of Murine Monoclonal Antibodies by Hybridoma Technology09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...